Ironwood Pharmaceuticals (IRWD) Projected to Post Earnings on Thursday

Ironwood Pharmaceuticals (NASDAQ:IRWD) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 20th. Analysts expect Ironwood Pharmaceuticals to post earnings of $0.10 per share and revenue of $93.85 million for the quarter.

Ironwood Pharmaceuticals Price Performance

NASDAQ IRWD opened at $2.00 on Wednesday. The firm has a market cap of $320.06 million, a PE ratio of -66.67 and a beta of 0.29. Ironwood Pharmaceuticals has a one year low of $1.59 and a one year high of $15.26. The stock’s 50 day simple moving average is $3.50 and its 200 day simple moving average is $4.04.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on IRWD shares. Craig Hallum decreased their price target on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. StockNews.com lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Finally, JMP Securities decreased their price objective on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.60.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other news, CEO Thomas A. Mccourt sold 139,064 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the transaction, the chief executive officer now owns 1,160,634 shares of the company’s stock, valued at $2,042,715.84. This represents a 10.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Michael Shetzline sold 41,269 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $72,633.44. Following the sale, the chief marketing officer now directly owns 554,007 shares in the company, valued at $975,052.32. The trade was a 6.93 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 192,381 shares of company stock worth $338,591. Insiders own 12.90% of the company’s stock.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.